Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 9NETWORK 5OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Uterine Cervical Neoplasms 1Solid Neoplasms 1SCLC 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Metastatic Solid Tumors 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

pembrolizumab 44Carboplatin 28Cisplatin 26Paclitaxel 24Bevacizumab 21human papillomavirus vaccine, L1 type 16, 18 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14atezolizumab 11Papillomavirus Vaccines 11Nivolumab 10tisotumab vedotin 8Vaccines, Synthetic 8Gemcitabine 8Colposcopy 8Topotecan 7fludarabine 6Vaccines 6Injections 6Cyclophosphamide 6spartalizumab 5balstilimab 5Pemetrexed 5Irinotecan 5Fulvestrant 5Docetaxel 5zimberelimab 4durvalumab 4Vinorelbine 4Ipilimumab 4Interleukin-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Cervical Neoplasms × Platinum × Clear all
NCT07497074 2026-03-27

JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2 Not yet recruiting
78 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡